Note 17. Stock compensation and other employee benefit plans

Stock compensation plans

On January 9, 2017, the Company’s board of directors adopted the 2017 Stock Incentive Plan (the “2017 Plan”). The Plan offered employees, directors and selected service providers the opportunity to acquire equity in the Company through grants of options, restricted stock awards, stock appreciation rights, restricted stock units (“RSUs”), and other stock awards, at exercise prices, if applicable, not less than the fair market value of the Company's common stock on the date of grant.

Our 2021 Stock Incentive Plan (the "2021 Plan"), which was adopted by our Board of Directors and approved by our stockholders on April 16, 2021, and became effective on April 27, 2021, provides for the grant of awards similar to the 2017 Plan, as well as stock bonuses and cash awards. The number of shares initially reserved for issuance under the 2021 Plan was 1,264,524 (on a post-split basis), which will automatically increase on January 1 of each calendar year prior to the tenth anniversary of the Plan's effective date in an amount equal to the lesser of (i) 4% of the total number of shares of common stock outstanding on the day prior (December 31st), and (ii) a number of shares of common stock determined by the compensation committee of the Company's board of directors. Through December 31, 2024, an additional 1,292,392 shares (on a post-split basis) became available for issuance pursuant to the automatic increase provisions of the 2021 Plan, resulting in a total number of shares authorized for issuance under the 2021 Plan of 2,556,916 (on a post-split basis).

On August 16, 2024, we filed a registration statement on Form S-8 to register an additional 650,000 shares (on a post-split basis) of common stock for issuance upon the vesting and settlement of time-based RSUs, in accordance with the terms of the Restricted Stock Unit Inducement Award Agreement, by and between the Company and Yann Brandt and the vesting and settlement of performance-based RSUs, in accordance with the terms of the Share Target Restricted Stock Unit Inducement Award Agreement by and between the Company and Yann Brandt (collectively, the "Employment Inducement Awards"). The Employment Inducement Awards were granted effective August 19, 2024, in connection with Mr. Brandt's commencement of employment as our President and Chief Executive Officer.

On July 1, 2022, we filed a registration statement on Form S-8 to register 500,000 (on a post-split basis) shares of common stock for issuance upon the settlement of RSUs and the exercise of stock options previously granted under the 2017 Plan that remain outstanding. No new awards have been or will be granted under the 2017 Plan following the effectiveness of our 2021 Plan on April 27, 2021.

Concurrent with the adoption of the 2021 Plan, we also adopted the 2021 Employee Stock Purchase Plan (the "2021 ESPP Plan") in order to provide employees of the Company and its designated subsidiaries with an opportunity to purchase the Company's common stock through accumulated payroll deductions at 85% of the stock's fair market value. As of December 31, 2024, this plan has not yet been implemented internally within the Company, and no purchases of common stock have been made pursuant to the 2021 ESPP Plan.

Stock options generally vest between two and four years from the date of grant, and, for those remaining outstanding as of December 31, 2024, have only service-based vesting conditions.

RSU grants may contain either (i) service-based vesting conditions or (ii) a combination of market or performance and service-based vesting conditions, which must be met in order to vest. Awards with service-based vesting conditions generally vest over a period of three to four years from the date of grant. Awards with market or performance-based vesting conditions will generally vest upon achievement of the related targets, providing the employee continues to be employed at the date of vesting. Performance conditions in certain of our outstanding awards are based on the recipient achieving specified sales metrics whereas, market conditions in certain outstanding awards are based on the closing price of our common stock achieving specified levels for a period of time.

Generally, new shares of authorized common stock are issued to satisfy vesting or exercise of awards under both the 2017 and 2021 Stock Incentive Plans, although treasury shares are also available for issuance at our discretion.

Stock compensation expense for each period was as follows:

 

 

Year ended December 31,

 

(in thousands)

 

2024

 

 

2023

 

Cost of revenue

 

$

902

 

 

$

1,596

 

Research and development

 

 

344

 

 

 

541

 

Selling and marketing

 

 

345

 

 

 

718

 

General and administrative

 

 

3,821

 

 

 

5,440

 

Total stock compensation expense

 

$

5,412

 

 

$

8,295

 

 

Information relating to our outstanding option awards was as follows:

Options

 

Shares(*)

 

 

Weighted-average exercise price(*)

 

 

Weighted-average remaining contractual term (in years)

 

 

Intrinsic value (in thousands)

 

Outstanding as of December 31, 2023

 

 

241,553

 

 

$

18.20

 

 

 

 

 

 

 

Granted

 

 

1,200

 

 

$

4.90

 

 

 

 

 

 

 

Exercised

 

 

(12,629

)

 

$

0.69

 

 

 

 

 

 

 

Forfeited

 

 

(512

)

 

$

4.90

 

 

 

 

 

 

 

Expired

 

 

(9,959

)

 

$

4.75

 

 

 

 

 

 

 

Outstanding as of December 31, 2024

 

 

219,653

 

 

$

19.73

 

 

 

6.30

 

 

$

240

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested at December 31, 2024 or expected to vest in the future

 

 

219,653

 

 

$

19.73

 

 

 

6.30

 

 

$

240

 

Exercisable at December 31, 2024

 

 

196,465

 

 

$

21.27

 

 

 

5.99

 

 

$

239

 

Unvested and expected to vest in the future

 

 

23,188

 

 

$

6.65

 

 

 

8.94

 

 

$

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2024:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation cost not yet recognized (in thousands)

 

 

 

 

 

 

 

 

 

 

$

108

 

Weighted-average remaining expense recognition period (in years)

 

 

 

 

 

 

 

 

 

 

 

0.54

 

___________

* -

Shares and weighted-average exercise prices have been revised to reflect the Reverse Stock Split, effective November 29, 2024.

Assumptions used to value option awards were as follows:

 

 

Year ended December 31,

 

 

 

2024

 

 

2023

 

Black-Scholes-Merton pricing formula weighted-average assumptions:

 

 

 

 

 

 

Expected life (in years)

 

 

1.00

 

 

 

5.50

 

Risk-free interest rate

 

 

4.94

%

 

 

4.16

%

Volatility

 

 

97.51

%

 

 

97.51

%

Dividend yield

 

 

0.00

%

 

 

0.00

%

 

 

 

 

 

 

 

Valuations(*):

 

 

 

 

 

 

Grant-date fair value per option(*)

 

$

1.90

 

 

$

5.20

 

Intrinsic value of options exercised (in thousands)

 

$

39

 

 

$

1,324

 

Average intrinsic value per share of options exercised

 

$

3.10

 

 

$

18.40

 

 

___________

* -

Grant-date fair values per option have been revised to reflect the Reverse Stock Split, effective November 29, 2024.

 

Information relating to our outstanding restricted stock unit awards was as follows:

 

 

Shares(*)

 

 

Weighted-average grant date fair value(*)

 

Restricted stock units:

 

 

 

 

 

 

Nonvested as of December 31, 2023

 

 

1,189,114

 

 

$

18.70

 

Granted

 

 

1,057,466

 

 

$

2.62

 

Vested

 

 

(379,833

)

 

$

23.04

 

Forfeited

 

 

(300,307

)

 

$

13.35

 

Nonvested as of December 31, 2024

 

 

1,566,440

 

 

$

5.97

 

 

 

 

 

 

 

 

Restricted stock unit vesting conditions:

 

 

 

 

 

 

Service-based vesting

 

 

700,786

 

 

$

11.47

 

Performance conditions and service-based vesting

 

 

150,000

 

 

$

5.63

 

Market conditions and service-based vesting

 

 

715,654

 

 

$

0.67

 

Nonvested as of December 31, 2024

 

 

1,566,440

 

 

$

5.97

 

 

 

 

 

 

 

 

At December 31, 2024:

 

 

 

 

 

 

Stock-based compensation cost not yet recognized (in thousands)

 

 

 

 

$

7,224

 

Weighted-average remaining expense recognition period (in years)

 

 

 

 

 

1.41

 

___________

* -

Shares and weighted-average grant date fair values have been revised to reflect the Reverse Stock Split, effective November 29, 2024.

The weighted average grant date fair value of RSUs granted during the year ended December 31, 2023 was $15.40 per RSU (on a post-split basis). The total fair value of RSUs vested was approximately $8.8 million and $15.1 million during the years ended December 31, 2024 and 2023, respectively.

Other employee benefit plans

We sponsor a 401(k) savings plan for our U.S. employees, whereby the employees can elect to make pre- or post-tax contributions, subject to certain limitations. We make matching contributions equal to 100% of the first 3% and 50% of the next 2% of an employee's contribution. Employee and company contributions are both immediately vested. Company matching contributions were approximately $0.5 million and $0.6 million for the years ending December 31, 2024 and 2023, respectively.

Employees are also eligible to participate in various employee welfare benefit plans, including medical, dental, prescription and life insurance, in which the Company pays a portion of the cost. All such plans are unfunded.

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.